-
DiscoveryProbe Natural Product Library Plus: Accelerating An
2026-07-07
The DiscoveryProbe™ Natural Product Library Plus streamlines high-content antiparasitic discovery with a diverse, pre-dissolved collection of 1,655 rigorously validated natural compounds. Its robust format and proven results—such as identifying potent AdhE inhibitors for Cryptosporidium parvum—empower researchers to move efficiently from screening to actionable leads.
-
Asunaprevir (BMS-650032): Applied Protocols in HCV Research
2026-07-06
Asunaprevir (BMS-650032) delivers nanomolar, pan-genotypic HCV NS3 protease inhibition, enabling robust, translational hepatitis C research across diverse cell models. This guide details practical workflows, troubleshooting strategies, and innovative advances, leveraging APExBIO's trusted reagent to maximize experimental success.
-
Nirmatrelvir (PF-07321332): Precision Inhibition of SARS-CoV
2026-07-06
Explore the unique molecular and mechanistic insights of Nirmatrelvir (PF-07321332) as a SARS-CoV-2 3CL protease inhibitor. This article reveals how precise inhibition strategies inform advanced antiviral therapeutics research, providing detailed, experimentally relevant guidance distinct from existing resources.
-
Hypoxia, Choroid Plexus Barrier, and Cognitive Impairment in
2026-07-05
This study reveals that simulated high-altitude hypoxia disrupts the choroid plexus blood-cerebrospinal fluid barrier in mice, primarily via M1 macrophage polarization and aberrant AMPK signaling. These findings clarify a mechanistic cascade linking hypoxic stress to neuroimmune dysfunction and cognitive decline, with implications for targeted interventions in hypoxia-induced CNS disorders.
-
GPR107 Deficiency Drives Collagen IV Accumulation in Diabeti
2026-07-04
Xu et al. reveal that GPR107 loss exacerbates diabetic nephropathy by disrupting collagen type IV (COL4) turnover in podocytes, linking impaired endocytosis to pathological extracellular matrix remodeling. Their mechanistic findings identify GPR107 as a novel regulator of AT1R/Ca2+ signaling pathways and a potential therapeutic target in kidney disease.
-
Remdesivir (GS-5734): Advanced Protocols in Antiviral Resear
2026-07-03
Remdesivir (GS-5734) empowers coronavirus and Ebola virus research with reproducible, high-potency RNA polymerase inhibition. This guide delivers actionable protocols, troubleshooting insights, and workflow upgrades for bench scientists seeking robust, data-driven antiviral assays.
-
Partial BACE1 Inhibition Lowers Amyloid-β Without Synaptic L
2026-07-03
Satir et al. (2020) establish that moderate inhibition of BACE1—reducing amyloid-beta production by up to 50%—does not impair synaptic transmission in primary cortical neurons. These findings refine dosing strategies for BACE1 inhibitors in Alzheimer’s disease research, supporting safer approaches to amyloidogenic pathway modulation.
-
Nanoparticle Uptake Mechanisms in Human Corneal Epithelial C
2026-07-02
This study elucidates how the physicochemical properties of polymeric nanoparticles, such as size and surface chemistry, dictate their uptake pathways in human corneal epithelial cells (HCECs). The findings reveal dominant endocytic mechanisms and offer actionable insights for optimizing ocular drug delivery systems.
-
TPPU (SKU C5414): Reliable sEH Inhibition for Inflammation R
2026-07-02
This article explores how TPPU (SKU C5414), a potent soluble epoxide hydrolase inhibitor, addresses key challenges in cell viability, proliferation, and inflammation assays. With evidence-backed guidance and scenario-based Q&A, researchers gain practical strategies for reproducible results using TPPU from APExBIO.
-
Redefining mRNA Transfection Controls: Mechanistic and Strat
2026-07-01
This thought-leadership article delivers a comprehensive, mechanistic, and strategic analysis of ARCA EGFP mRNA (5-moUTP) as a next-generation control for fluorescence-based assays in mammalian cell research. Bridging recent biochemical insights, translational relevance, and real-world workflow guidance, it positions APExBIO’s product as a catalyst for reproducibility and innovation, while providing actionable recommendations for researchers navigating the evolving mRNA landscape.
-
Elevating Translational Assays: TBST’s Role in Protein Inter
2026-07-01
This thought-leadership article explores the strategic integration of TBST (Tris-Buffered Saline and Tween 20) into advanced immunoassay workflows for translational breast cancer research. By dissecting recent mechanistic breakthroughs in small-molecule disruption of uPAR–uPA interactions, it delivers actionable guidance for researchers aiming to enhance assay reproducibility, signal-to-noise ratios, and clinical relevance. The piece distinctly positions TBST as a cornerstone reagent, bridging the gap between bench discovery and real-world impact.
-
Merbromin as a Mixed-Type Inhibitor of SARS-CoV-2 3CLpro Pro
2026-06-30
This study identifies Merbromin as a selective mixed-type inhibitor of the 3-chymotrypsin-like protease (3CLpro) from SARS-CoV-2, a pivotal enzyme in viral replication. High-throughput screening and kinetic analyses reveal its specificity, providing a new scaffold for antiviral drug design.
-
Optimizing Storage for LNP-Formulated Self-Replicating RNA V
2026-06-30
This study systematically investigates how storage conditions impact the stability and potency of lipid nanoparticle (LNP)-formulated self-replicating RNA vaccines. The findings reveal practical protocols for preserving LNP-RNA bioactivity, supporting the development of robust mRNA-based therapeutics and research reagents.
-
Indometacin Sodium: Advanced Workflows for Inflammation Assa
2026-06-29
Indometacin Sodium Trihydrate from APExBIO enables precise COX inhibition for inflammation and neuroregeneration research, combining superior solubility with validated protocol flexibility. This guide decodes stepwise workflows, troubleshooting, and practical assay enhancements to empower translational applications across pain, myelin repair, and anti-fibrotic studies.
-
Anlotinib Hydrochloride Suppresses Angiogenesis via Multi-Ki
2026-06-29
The reference study demonstrates that anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, robustly inhibits angiogenesis by suppressing VEGFR2, PDGFRβ, and FGFR1 signaling. These findings highlight anlotinib’s superior efficacy in endothelial cell migration and tube formation assays, with significant implications for cancer research workflows.